Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Flocath Solo catheter paediatric olive tip 8Ch-10Ch
21020001039
|
Flocath Solo catheter paediatric olive tip 8Ch-10Ch | Catheters | Appliances | No data available |
|
Flolan 1.5mg (pH10.5) inf vials
0208010E0BBABAB
|
Flolan | Epoprostenol sodium | Cardiovascular System | No data available |
|
Flolan 1.5mg inf vials
0208010E0BBACAE
|
Flolan | Epoprostenol sodium | Cardiovascular System | No data available |
|
Flolan 500microgram (pH10.5) inf vials
0208010E0BBAAAA
|
Flolan | Epoprostenol sodium | Cardiovascular System | No data available |
|
Flolan 500microgram inf vials
0208010E0BBADAF
|
Flolan | Epoprostenol sodium | Cardiovascular System | No data available |
|
Flomax MR 400microgram capsules
0704010U0BBAAAA
|
Flomax MR | Tamsulosin hydrochloride | Obstetrics, Gynaecology and Urinary-Tract Disorders | No data available |
|
Florinef 100microgram tablets
0603010I0BBAAAC
|
Florinef | Fludrocortisone acetate | Endocrine System | No data available |
|
Floxapen 125mg/5ml syrup
0501012H0BBAAAA
|
Floxapen (Liquid/Powder) | Flucloxacillin magnesium | Infections | No data available |
|
Floxapen 1g powder for solution for injection vials
0501012G0BBAGAE
|
Floxapen (Capsule/Injection) | Flucloxacillin sodium | Infections | No data available |
|
Floxapen 250mg capsules
0501012G0BBAAAA
|
Floxapen (Capsule/Injection) | Flucloxacillin sodium | Infections | No data available |
|
Floxapen 250mg powder for solution for injection vials
0501012G0BBAEAC
|
Floxapen (Capsule/Injection) | Flucloxacillin sodium | Infections | No data available |
|
Floxapen 500mg capsules
0501012G0BBABAB
|
Floxapen (Capsule/Injection) | Flucloxacillin sodium | Infections | No data available |
|
Floxapen 500mg powder for solution for injection vials
0501012G0BBAFAD
|
Floxapen (Capsule/Injection) | Flucloxacillin sodium | Infections | No data available |
|
Flu Relief with Decongestant capsules
0407010ABBGAAAC
|
Galpharm (Paracetamol/phenylephrine hydrochloride) | Paracetamol and phenylephrine hydrochloride | Central Nervous System | No data available |
|
Flu Strength Hot Lemon Pdrs 1g oral pdr sach (Bell,Sons&Co)
0407010H0CSABDG
|
Bell's (Paracetamol) | Paracetamol | Central Nervous System | No data available |
|
Flu Strength Hot Lemon Powders 1g oral pdr sach (Galpharm)
0407010H0CPAADG
|
Galpharm (Paracetamol) | Paracetamol | Central Nervous System | No data available |
|
Flu/Vac/Split 15microg strain inj 0.1ml pfs
1404000H0AAAIAI
|
Influenza | Influenza | Immunological Products and Vaccines | No data available |
|
Flu/Vac/Split 9microg strain inj 0.1ml pfs
1404000H0AAAHAH
|
Influenza | Influenza | Immunological Products and Vaccines | No data available |
|
Fluarix vacc inj 0.5ml pre-filled syringes
1404000H0BFAAAK
|
Fluarix | Influenza | Immunological Products and Vaccines | No data available |
|
Flublok Quadrivalent vaccine (recombinant) inj 0.5ml pfs
1404000H0CDAAAP
|
Flublok Quadrivalent | Influenza | Immunological Products and Vaccines | No data available |
|
Fluclomix 250 capsules
0501012G0BGACAA
|
Fluclomix | Flucloxacillin sodium | Infections | No data available |
|
Fluclomix 500 capsules
0501012G0BGADAB
|
Fluclomix | Flucloxacillin sodium | Infections | No data available |
|
Flucloxacillin 125mg/5ml oral suspension
0501012H0AAAAAA
|
Flucloxacillin magesium | Flucloxacillin magnesium | Infections | No data available |
|
Flucloxacillin 2g powder for solution for injection vials
0501012G0AAARAR
|
Flucloxacillin sodium | Flucloxacillin sodium | Infections | No data available |
|
Fluconazole 100mg/50ml solution for infusion bottles
0502010B0AAAMAM
|
Fluconazole | Fluconazole | Infections | No data available |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.